NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Ltd. Kck sold 3,720 shares of NeuroPace stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $6.10, for a total transaction of $22,692.00. Following the sale, the insider now directly owns 5,499,065 shares in the company, valued at approximately $33,544,296.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Ltd. Kck also recently made the following trade(s):
- On Friday, October 18th, Ltd. Kck sold 4,878 shares of NeuroPace stock. The shares were sold at an average price of $6.29, for a total value of $30,682.62.
- On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total value of $45,333.00.
- On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The shares were sold at an average price of $6.54, for a total transaction of $26,362.74.
- On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The stock was sold at an average price of $6.35, for a total transaction of $16,332.20.
- On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total transaction of $19,050.30.
- On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The stock was sold at an average price of $6.66, for a total transaction of $32,700.60.
- On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The shares were sold at an average price of $6.97, for a total value of $23,126.46.
NeuroPace Price Performance
NPCE stock opened at $6.04 on Friday. NeuroPace, Inc. has a 1 year low of $5.66 and a 1 year high of $18.15. The firm has a market capitalization of $176.37 million, a P/E ratio of -5.54 and a beta of 1.78. The company has a debt-to-equity ratio of 5.97, a current ratio of 6.37 and a quick ratio of 5.47. The business’s 50-day moving average is $7.00 and its two-hundred day moving average is $8.23.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on NPCE. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price objective on shares of NeuroPace in a research note on Wednesday, August 14th. Wells Fargo & Company dropped their target price on NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Finally, Morgan Stanley reduced their price target on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.
View Our Latest Stock Analysis on NeuroPace
Hedge Funds Weigh In On NeuroPace
Institutional investors and hedge funds have recently modified their holdings of the company. Hillsdale Investment Management Inc. acquired a new stake in NeuroPace in the first quarter valued at $155,000. Rhumbline Advisers purchased a new position in shares of NeuroPace in the 2nd quarter valued at about $111,000. Financial Advocates Investment Management raised its position in shares of NeuroPace by 50.0% during the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock worth $113,000 after acquiring an additional 5,000 shares in the last quarter. XTX Topco Ltd raised its position in shares of NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after acquiring an additional 8,643 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in NeuroPace during the second quarter worth approximately $257,000. Institutional investors and hedge funds own 78.83% of the company’s stock.
About NeuroPace
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Featured Articles
- Five stocks we like better than NeuroPace
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What Investors Need to Know to Beat the Market
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What Does a Stock Split Mean?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.